NCT06376435View on ClinicalTrials.gov

A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia

Not yet recruitingOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

April 20, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions

Cancer, Therapy-Related

Interventions

DRUG

Herombopag Olamine Tablets

Herombopag Olamine；combined rhTPO;combined IL-11

All Listed Sponsors

lead

Hebei Medical University Fourth Hospital

OTHER